000-51598 | 77-0259335 | |
(Commission File Number) | (IRS Employer Identification No.) |
8 Crosby Drive, Bedford, Massachusetts | 01730 | |
(Address of Principal Executive Offices) | (Zip Code) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 | Results of Operations and Financial Condition. |
Item 9.01 | Financial Statements and Exhibits. |
99.1 | Press Release issued by the registrant on October 21, 2009,
furnished herewith. |
iRobot Corporation |
||||
October 21, 2009 | By: | /s/ Glen D. Weinstein | ||
Name: | Glen D. Weinstein | |||
Title: | General Counsel and Secretary | |||
Exhibit Number | Description | |||
99.1 | Press Release issued by the registrant on October 21, 2009, furnished herewith. |
Contacts: |
||
Elise Caffrey
|
Nancy Smith | |
Investor Relations
|
Media Relations | |
iRobot Corp.
|
iRobot Corp. | |
(781) 430-3003
|
(781) 430-3323 | |
ecaffrey@irobot.com
|
nsmith@irobot.com |
| International home robot revenue in the third quarter of 2009 increased 55 percent from the third quarter of 2008 and comprised half of total home robot revenue in the quarter. | |
| Government & Industrial Robots division received more than $55 million in orders from the U.S. Government during the quarter and has 100 percent visibility on its full-year revenue expectations. | |
| In the first nine months of 2009, operating cash flow was $24.6 million, compared with cash used in operations of $0.3 million in the first nine months of 2008, as continued aggressive management led to a $17.9 million reduction of inventory at quarter end versus last year. |
Fiscal Year 2009:
|
||
Revenue
|
$295 $305 million | |
Adjusted EBITDA
|
$15 $18 million | |
Earnings Per Share
|
$0.02 $0.06 | |
Q4 2009: |
||
Revenue
|
$98 $108 million | |
Adjusted EBITDA
|
$7 $10 million | |
Earnings Per Share
|
$0.09 $0.13 |
For the three months ended | For the nine months ended | |||||||||||||||
September 26, | September 27, | September 26, | September 27, | |||||||||||||
2009 | 2008 | 2009 | 2008 | |||||||||||||
Revenue |
||||||||||||||||
Product revenue |
$ | 69,080 | $ | 87,224 | $ | 171,380 | $ | 198,475 | ||||||||
Contract revenue |
9,539 | 5,191 | 25,515 | 18,444 | ||||||||||||
Total |
78,619 | 92,415 | 196,895 | 216,919 | ||||||||||||
Cost of Revenue |
||||||||||||||||
Product revenue |
46,415 | 58,371 | 116,952 | 138,948 | ||||||||||||
Contract revenue |
8,009 | 5,114 | 23,133 | 17,213 | ||||||||||||
Total |
54,424 | 63,485 | 140,085 | 156,161 | ||||||||||||
Gross Margin |
24,195 | 28,930 | 56,810 | 60,758 | ||||||||||||
Operating Expense |
||||||||||||||||
Research & development |
3,159 | 4,940 | 10,633 | 13,631 | ||||||||||||
Selling & marketing |
9,514 | 10,522 | 27,420 | 35,451 | ||||||||||||
General & administrative |
7,420 | 7,578 | 21,915 | 21,696 | ||||||||||||
Total |
20,093 | 23,040 | 59,968 | 70,778 | ||||||||||||
Operating income (loss) |
4,102 | 5,890 | (3,158 | ) | (10,020 | ) | ||||||||||
Other income (expense), net |
112 | 180 | (96 | ) | 917 | |||||||||||
Pre-tax income (loss) |
4,214 | 6,070 | (3,254 | ) | (9,103 | ) | ||||||||||
Income tax expense (benefit) |
1,620 | 2,218 | (1,452 | ) | (4,437 | ) | ||||||||||
Net income (loss) |
$ | 2,594 | $ | 3,852 | $ | (1,802 | ) | $ | (4,666 | ) | ||||||
Net income (loss) per common share: |
||||||||||||||||
Basic |
$ | 0.10 | $ | 0.16 | $ | (0.07 | ) | $ | (0.19 | ) | ||||||
Diluted |
$ | 0.10 | $ | 0.15 | $ | (0.07 | ) | $ | (0.19 | ) | ||||||
Shares used in Per Common Share Calculations: |
||||||||||||||||
Basic |
25,025 | 24,712 | 24,974 | 24,614 | ||||||||||||
Diluted |
25,670 | 25,536 | 24,974 | 24,614 | ||||||||||||
Stock-based compensation included in above figures: |
||||||||||||||||
Cost of product revenue |
$ | 267 | $ | 184 | $ | 758 | $ | 554 | ||||||||
Cost of contract revenue |
139 | 127 | 464 | 300 | ||||||||||||
Research & development |
89 | 131 | 187 | 226 | ||||||||||||
Selling & marketing |
351 | 305 | 1,006 | 733 | ||||||||||||
General & administrative |
1,016 | 1,090 | 2,944 | 2,495 | ||||||||||||
Total |
$ | 1,862 | $ | 1,837 | $ | 5,359 | $ | 4,308 | ||||||||
September 26, | December 27, | |||||||
2009 | 2008 | |||||||
Assets |
||||||||
Cash and equivalents |
$ | 62,747 | $ | 40,852 | ||||
Accounts receivable, net |
43,934 | 35,930 | ||||||
Unbilled revenues |
2,537 | 2,014 | ||||||
Inventory |
24,653 | 34,560 | ||||||
Deferred tax assets |
7,295 | 7,299 | ||||||
Other current assets |
4,430 | 3,340 | ||||||
Total current assets |
145,596 | 123,995 | ||||||
Property, plant and equipment, net |
20,401 | 22,929 | ||||||
Deferred tax assets |
4,508 | 4,508 | ||||||
Other assets |
11,877 | 12,246 | ||||||
Total assets |
$ | 182,382 | $ | 163,678 | ||||
Liabilities and stockholders equity |
||||||||
Accounts payable |
$ | 27,787 | $ | 19,544 | ||||
Accrued expenses |
11,672 | 10,989 | ||||||
Accrued compensation |
10,846 | 6,393 | ||||||
Deferred revenue and customer advances |
4,244 | 2,632 | ||||||
Total current liabilities |
54,549 | 39,558 | ||||||
Long term liabilities |
4,122 | 4,444 | ||||||
Stockholders equity |
123,711 | 119,676 | ||||||
Total liabilities and stockholders equity |
$ | 182,382 | $ | 163,678 | ||||
For the three months ended | For the nine months ended | |||||||||||||||
September 26, | September 27, | September 26, | September 27, | |||||||||||||
2009 | 2008 | 2009 | 2008 | |||||||||||||
Cash flows from operating activities: |
||||||||||||||||
Net income (loss) |
$ | 2,594 | $ | 3,852 | $ | (1,802 | ) | $ | (4,666 | ) | ||||||
Adjustments to reconcile net income (loss)
to net cash provided by (used in) operating
activities: |
||||||||||||||||
Depreciation and amortization |
2,289 | 1,844 | 6,153 | 5,135 | ||||||||||||
Loss on disposal of property and equipment |
74 | 12 | 176 | 80 | ||||||||||||
Stock-based compensation |
1,862 | 1,837 | 5,359 | 4,308 | ||||||||||||
In-process research and development
relating to acquisition of Nekton
Research LLC |
| 200 | | 200 | ||||||||||||
Benefit from deferred tax assets |
164 | | (347 | ) | | |||||||||||
Non-cash director deferred compensation |
33 | 24 | 99 | 71 | ||||||||||||
Changes in operating assets and liabilities
(use) source
|
||||||||||||||||
Accounts receivable |
(12,643 | ) | (21,598 | ) | (8,004 | ) | 1,830 | |||||||||
Unbilled revenue |
922 | (82 | ) | (523 | ) | (28 | ) | |||||||||
Inventory |
3,985 | 692 | 9,907 | 2,626 | ||||||||||||
Other assets |
1,052 | 1,186 | (1,111 | ) | (6,930 | ) | ||||||||||
Accounts payable |
6,679 | 7,192 | 8,243 | (13,540 | ) | |||||||||||
Accrued expenses |
706 | 1,226 | 673 | 1,405 | ||||||||||||
Accrued compensation |
3,819 | 1,481 | 4,453 | 3,503 | ||||||||||||
Deferred revenue |
1,270 | 1,755 | 1,612 | 1,127 | ||||||||||||
Change in long term liabilities |
(107 | ) | (107 | ) | (322 | ) | 4,552 | |||||||||
Net cash provided by (used in) operating
activities |
12,699 | (486 | ) | 24,566 | (327 | ) | ||||||||||
Cash flows from investing activities: |
||||||||||||||||
Purchase of property and equipment |
(953 | ) | (1,312 | ) | (3,401 | ) | (13,589 | ) | ||||||||
Purchase of Nekton Research LLC, net of cash
received |
| (9,745 | ) | | (9,745 | ) | ||||||||||
Purchases of investments |
| | | (29,997 | ) | |||||||||||
Sales of investments |
| 1,300 | | 30,350 | ||||||||||||
Net cash used in investing activities |
(953 | ) | (9,757 | ) | (3,401 | ) | (22,981 | ) | ||||||||
Cash flows from financing activities: |
||||||||||||||||
Proceeds from stock option exercises |
36 | 176 | 495 | 908 | ||||||||||||
Income tax withholding payment associated
with restricted stock vesting |
(67 | ) | | (76 | ) | | ||||||||||
Borrowings under revolving line of credit |
| 5,500 | | 5,500 | ||||||||||||
Tax benefit of excess stock based
compensation deductions |
43 | 322 | 311 | 680 | ||||||||||||
Net cash provided by financing activities |
12 | 5,998 | 730 | 7,088 | ||||||||||||
Net increase (decrease) in cash and cash
equivalents |
11,758 | (4,245 | ) | 21,895 | (16,220 | ) | ||||||||||
Cash and cash equivalents, at beginning of
period |
50,989 | 14,760 | 40,852 | 26,735 | ||||||||||||
Cash and cash equivalents, at end of period |
$ | 62,747 | $ | 10,515 | $ | 62,747 | $ | 10,515 | ||||||||
For the three months ended | For the nine months ended | |||||||||||||||
September 26, | September 27, | September 26, | September 27, | |||||||||||||
2009 | 2008 | 2009 | 2008 | |||||||||||||
Revenue by business unit
(in thousands): |
||||||||||||||||
Home Robots
|
||||||||||||||||
Product |
$ | 44,331 | $ | 53,626 | $ | 111,253 | $ | 125,424 | ||||||||
Contract |
| | | 55 | ||||||||||||
Government & Industrial
|
||||||||||||||||
Product |
24,749 | 33,598 | 60,127 | 73,051 | ||||||||||||
Contract |
9,539 | 5,191 | 25,515 | 18,389 | ||||||||||||
$ | 78,619 | $ | 92,415 | $ | 196,895 | $ | 216,919 | |||||||||
Direct Revenue Home
Robots (in thousands) |
$ | 5,489 | $ | 6,777 | $ | 17,178 | $ | 22,514 | ||||||||
Product Lifecycle Revenue
Government & Industrial
(in thousands) |
$ | 5,368 | $ | 5,977 | $ | 14,299 | $ | 11,351 | ||||||||
International Revenue (in
thousands): |
||||||||||||||||
Home Robots |
$ | 22,017 | $ | 14,203 | $ | 59,296 | $ | 42,784 | ||||||||
Government & Industrial |
$ | 4,435 | $ | 4,360 | $ | 8,907 | $ | 5,570 | ||||||||
Average selling prices for
robot units: |
||||||||||||||||
Home Robots |
$ | 143 | $ | 138 | $ | 153 | $ | 150 | ||||||||
Government &
Industrial (in
thousands) |
$ | 122 | $ | 87 | $ | 100 | $ | 96 | ||||||||
Gross Margin by business
unit (in thousands): |
||||||||||||||||
Home Robots |
$ | 13,450 | $ | 14,867 | $ | 33,711 | $ | 33,695 | ||||||||
Government & Industrial |
10,745 | 14,063 | 23,099 | 27,063 | ||||||||||||
$ | 24,195 | $ | 28,930 | $ | 56,810 | $ | 60,758 | |||||||||
Units shipped by business
unit: |
||||||||||||||||
Home Robots (in
thousands) |
289 | 355 | 664 | 761 | ||||||||||||
Government & Industrial |
159 | 319 | 460 | 645 | ||||||||||||
Government & Industrial
Funded Backlog (in
thousands) |
$ | 71,038 | $ | 36,621 | $ | 71,038 | $ | 36,621 | ||||||||
Days sales outstanding |
54 | 48 | 54 | 48 | ||||||||||||
Inventory turnover |
7.5 | 5.5 | 7.5 | 5.5 | ||||||||||||
Net cash provided by (used
in) operating activities
(in thousands) |
$ | 12,699 | $ | (486 | ) | $ | 24,566 | $ | (327 | ) | ||||||
Headcount |
514 | 505 | 514 | 505 |
For the three months ended | For the nine months ended | |||||||||||||||
September 26, | September 27, | September 26, | September 27, | |||||||||||||
2009 | 2008 | 2009 | 2008 | |||||||||||||
Net income (loss) |
$ | 2,594 | $ | 3,852 | $ | (1,802 | ) | $ | (4,666 | ) | ||||||
Interest income, net |
(5 | ) | (205 | ) | (41 | ) | (1,034 | ) | ||||||||
Income tax expense (benefit) |
1,620 | 2,218 | (1,452 | ) | (4,437 | ) | ||||||||||
Depreciation |
2,150 | 1,803 | 5,763 | 5,094 | ||||||||||||
Amortization |
139 | 41 | 390 | 41 | ||||||||||||
EBITDA |
6,498 | 7,709 | 2,858 | (5,002 | ) | |||||||||||
Stock-based compensation expense |
1,862 | 1,837 | 5,359 | 4,308 | ||||||||||||
Adjusted EBITDA |
$ | 8,360 | $ | 9,546 | $ | 8,217 | $ | (694 | ) | |||||||